Browse drugs

…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…

…itis (LN) relapse in relation to LN induction treatment without Cyclophosphamide (Non-Cyc) or with Cyclophosphamide (Cyc) (A). Boxplots of methy…

…6% vs 51%, p=0.003), including after treatment discontinuation. Avacopan was associated with accelerated glucocorticoid tapering (≤5 mg/…

… baseline HRCT predicted PPF in patients with SSc-ILD receiving mycophenolate or cyclophosphamide therapy. Future independent prospective coh…

… AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen cons…

…ed that RDI is a critical determinant of outcome. Higher RDI of doxorubicin (HR 0.75−0.82) and cyclophosphamide (HR 0.97) was significantly…

…cline in use of cyclophosphamide from 2013 onwards. Ever-use of mycophenolate began to rise from the group recruited from1994 onwards and bio…

…ling is a central driver of systemic lupus erythematosus (SLE). Anifrolumab, an anti-IFNAR1 monoclonal antibody, improves outcomes in moder…

…t related adverse events was 66.7% (269 of 403 patients) in the carboplatin arm and 55.0% (222 of 404 patients) in the control arm. No trea…

…of conditions that cause inflammation and fibrosis in the lung. Cyclophosphamide (CYC) is considered for patients with rapidly worsening ILD to …

…. The mean disease duration was 7.4±6.4 years. All pts received prednisolone at mean dose of 10±4 mg/day. 11% of patients received cyclophos…

…temic sclerosis (SSc), improving overall survival compared with cyclophosphamide. However, 10–20% of patients relapse after AHSCT. Chimeric Anti…